Since joining Kenyon & Kenyon in 1999, Michael Levy has concentrated on patent litigation, client counseling, opinion work, due diligence, portfolio management and patent prosecution in the pharmaceutical, drug delivery, medical device, and chemical process fields.
Prior to joining the firm, Mr. Levy practiced intellectual property law in Philadelphia focusing on patent prosecution and litigation covering a wide variety of disciplines, including pharmaceuticals, coatings, microchip manufacturing, specialty chemicals and alternative energy technologies. Mr. Levy began his legal career practicing environmental law, particularly addressing liability and insurance coverage issues stemming from environmental contamination. Before attending law school, Mr. Levy worked as an engineer for an environmental and occupational health and safety consulting firm.
His representative matters include:
Warner-Lambert Company, et al v. Purepac Pharmaceutical, et al. (D.N.J) – A patent infringement action concerning Teva’s AB-rated generic equivalent to Pfizer’s Neurontin®. Obtained a favorable settlement two weeks into a scheduled seven-week jury trial in the District of New Jersey.
Boston Sci Scimed, et al v. Cordis Corporation, et al. (D. Del.) – Achieved significant victory in stent patent litigation. A jury found that Johnson & Johnson's CYPHER(r) drug-eluting stent infringes Boston Scientific's U.S. Patent 6,120,536. The jury also upheld the validity of the patent.
Purdue Research Foundation v. Sanofi-Synthelabo, S.A. (D.D.C.) – The U.S. District Court for the District of Columbia dismissed Purdue Research Foundation's case against our client Sanofi-Synthelabo, for lack of personal jurisdiction. The case involved a claim by Purdue for compensation for a cold remedy called pleconaril, which is patented by Sanofi. The decision follows an earlier victory for Sanofi in a related case in Indiana. The D.C. case becomes one of the few decisions addressing jurisdiction over non-resident patentees (35 U.S.C. § 293).
Purdue Research Foundation v. Sanofi-Synthelabo, S.A. (7th Cir.) – The Seventh Circuit affirmed the district court decision and dismissed the case, involving a patented anti-viral compound, against our client, Sanofi Syntholabo, S.A. (headquartered in Paris, France) for lack of personal jurisdiction in Indiana.